Markets:

Overview

News

Currencies

International

Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

9.410 +0.560 (+6.33%)

Streaming Delayed Price Updated: 3:21 PM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Analysts Holding As Pfizer Waits On Two Phase 3 Studies

February 24, 2023

Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.

Via MarketBeat

Topics Bankruptcy

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 13, 2023

Via Benzinga

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗

February 02, 2023

The company that remains still has a large pipeline of non-migraine assets.

Via Investor's Business Daily

Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy' ↗

January 18, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy."

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023 ↗

January 24, 2023

Via Benzinga

Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators' ↗

December 16, 2022

Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be on investors’ shopping list for 2023.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 ↗

January 04, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022 ↗

December 02, 2022

Via Benzinga

Jim Cramer Says This Stock Is Dynamite: 'I Do Not Want You To Do A Thing Other Than Ride It' ↗

December 01, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Williams Companies, Inc. (NYSE: WMB) is "terrific." He recommended buying the stock.

Via Benzinga

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

$41 Million Bet On This Biotechnology Stock? 3 Stocks Insiders Are Buying ↗

October 27, 2022

Although US stocks closed mostly lower on Wednesday, there were a few notable insider trades.

Via Benzinga

Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday ↗

October 24, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.

Via Benzinga

Moderna, Amazon, Tesla, And Other Big Gainers From Friday ↗

October 24, 2022

U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Intuitive Surgical, Netflix, ASML And Other Big Gainers From Wednesday ↗

October 20, 2022

U.S. stocks closed lower on Wednesday, with the Dow Jones dropping 100 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 18, 2022

Gainers

Via Benzinga

Why Olaplex Shares Dipped Around 57%; Here Are 75 Biggest Movers From Yesterday ↗

October 20, 2022

Gainers Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022 ↗

October 12, 2022

Upgrades

Via Benzinga

Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday ↗

October 11, 2022

Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 10, 2022

Gainers

Via Benzinga

Coinbase Global And 3 Other Stocks Insiders Are Buying ↗

October 07, 2022

Although US stocks closed lower on Thursday, there were a few notable insider trades.

Via Benzinga

Biohaven Ltd. Surges 7.6%: Is This An Indication Of Further Gains? ↗

October 07, 2022

Biohaven Ltd. shares ended the last trading session 7.6% higher at $13.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares...

Via Talk Markets

Pinterest, Perion Network And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

October 06, 2022

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Why WISeKey International Is Trading Higher By Over 20%; Here Are 29 Stocks Moving Premarket ↗

October 06, 2022

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 89.4% to $0.2655 in pre-market trading. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For...

Via Benzinga

Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday ↗

October 06, 2022

Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

October 04, 2022

On Tuesday, 44 companies hit new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 04, 2022

Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million.

Via Benzinga

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

October 03, 2022

From Pfizer Inc.

Via Business Wire

IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle ↗

September 29, 2022

The drug has faced two advisory committees and a delayed review date.

Via Investor's Business Daily

Biohaven's ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months ↗

September 29, 2022

Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN) announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).

Via Benzinga

Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test ↗

September 29, 2022

Patients didn't show any improvements in a study meant to test multiple drugs.

Via Investor's Business Daily

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biohaven Ltd. Common Shares (NY:BHVN)

All News about Biohaven Ltd. Common Shares

Resources